Antiverse

🎉 Big news: we're now working with Nxera Pharma to design novel GPCR-targeted antibodies for multiple diseases of high unmet need! Our multi-year partnership with Nxera will aim to bring transformative antibody therapies to patients. Approximately 220 GPCRs with known disease links are currently undrugged and antibodies are an essential tool to change this. This collaboration combines our expertise in generative AI antibody design with Nxera’s NxWave™ platform – a powerful tool for GPCR target selection, validation and structural determination. The first project will be aimed at designing antibodies with agonistic functions for a challenging GPCR target. Read the press release ➡️ https://lnkd.in/eNfzDXrZ #Antiverse

AI-built epitope-specific libraries are the future of antibody drug design. Antibodies designed through epitope-specific libraries offer a rational approach to drug discovery, as they focus on structural and sequence data to generate high-confidence candidates. Precision is especially vital for challenging targets like GPCRs and ion channels, where binders are rare. Conventional antibody discovery methods often rely on random sampling, making them inefficient for more complicated targets. Our AI-powered platform engineers epitope-specific libraries to address this challenge, opening the door to the development of new therapies for diseases with high unmet needs. Learn more about our generative AI antibody design engine ➡️ https://www.antiverse.io/ #Antiverse #DrugDiscovery

Over 220 G-protein coupled receptors (GPCRs) with known links to diseases remain undrugged. Why? GPCRs are some of the most challenging targets in drug discovery due to their limited extracellular presence, dynamic conformations and similarities to other receptor subtypes. Traditional methods of drug discovery often rely on random sampling. However, binders for challenging targets like GCPRs are rare, meaning many campaigns often fail. Consequently, many GPCR drugs are yet to be created, which could have profound impacts on patients' lives. Using a computational approach and generative AI to build epitope-specific libraries, we’re helping overcome these challenges to support our partners in bringing therapies to patients faster. Learn more about our AI antibody design engine ➡️ https://www.antiverse.io/ #Pharma #DrugDiscovery #AI #Biotechnology #Antiverse

We recently partnered with Nxera Pharma to design antibodies for multiple GPCR targets. In this month's newsletter, we uncover more about why we are working together and how our combined platforms can tackle some of the industry's most challenging targets. Follow Antiverse! 🧑🔬 #pharma #biotech #GPCR

To date, most successful drug discovery programmes for GPCRs and ion channels have focused on small molecules. However, many challenging targets require new, innovative solutions. That's why we're focused on antibody discovery. 🧬 Antibodies bring a host of benefits over small molecules – including higher target selectivity and bioavailability, which reduces the likelihood of side effects – but discovering antibodies for GPCRs and ion channels is notoriously tricky, due to their dynamic structures and hard-to-reach binding sites: 1️⃣ Receptor epitopes can be only a few atoms long, making it difficult to find successful binders 2️⃣ The cells surface is busy with many kinds of receptors, blocking antibodies from their targets Using generative AI, we build epitope-specific antibody libraries. These libraries are designed against the epitope of interest, boosting our predictive accuracy and the likelihood of discovering functional binders. Find out more about our platform ➡️ https://lnkd.in/eJFKw7jz #DrugDiscovery #Biotechnology #Antiverse

Some highlights from our headquarters in Cardiff, Wales 🏴󠁧󠁢󠁷󠁬󠁳󠁿 Thanks to Andrew Moyes, PhD and Luke Bateman for the photographs! #antibodydiscovery #machinelearning #cardiff

Meet our founders! 👋 With a combined 30 years experience, Murat Tunaboylu and Ben H. are the duo leading the charge at Antiverse. Murat, CEO 🦾 With a background in software engineering, bioinformatics and robotics, Murat co-founded Antiverse in a bid to apply his technical nous to change patients' lives. He also has experience at Thermo Fisher, where he worked on automated DNA synthesis workflows. Ben, CTO 🧬 With a background in engineering, and a named inventor on several patents, Ben finds his inspiration through the process of learning and solving challenging problems that fulfill unmet needs in society. Learn more about our team ➡️ https://lnkd.in/eRQKepp3 #Pharma #DrugDiscovery #AI #Biotechnology #Antiverse

Please give a warm welcome to our Wellbeing Officer, Pico! This fuzzy ball of energy joined us today to keep our team healthy and motivated. We couldn't resist the gravity of his presence–like a fluffly black hole, we were pulled into his fun-filled world. Fun fact about Pico: He is the first dog to break the sound barrier with the power of excitement. #officedog #antibodydiscovery #morale

I'm looking forward to attending Biotech Showcase 2025! Join me in San Francisco, January 13–15, 2025 https://lnkd.in/e-gNvp73 #BiotechShowcase Informa Connect

🗞️ We're proud to be in The Times in a feature on the promise of AI in drug discovery! Our CEO Murat Tunaboylu talked to journalist Katie Prescott about our partnership with Nxera Pharma, how we are designing antibodies for challenging targets, and how our generative AI technology is shifting the dial from drug “discovery”, to drug “design”. Read the full feature on how pharma firms are betting on AI ➡️ https://lnkd.in/eBEFdu4y #Antiverse